SCHEMBL9254112

SCHEMBL9254112

CC(C)C(=O)c1cccc(N)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.55
NPC1 O15118 1/20 0.51
MITF O75030 1/20 0.51
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.51
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
RECQL P46063 2/20 0.50
DBH P09172 1/20 0.50
GAA P10253 1/20 0.50
F2 P00734 1/20 0.47
PLG P00747 1/20 0.47
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
KDM4C Q9H3R0 1/20 0.46
ADRB2 P07550 2/20 0.46
ADRB1 P08588 2/20 0.46
ADRB3 P13945 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9041395 0.86 PBRM1 (0.53) PBRM1NPC1MITFLMNAPOLB
SCHEMBL7945435 0.85 GAA (0.59) KDM4EALDH1A1RECQLDBHGAA
SCHEMBL21200752 0.80 ACHE (0.56) PBRM1NPC1MITFLMNAPOLB
SCHEMBL27661995 0.79 ALDH1A1 (0.50) PBRM1NPC1MITFLMNAPOLB
SCHEMBL11271082 0.79 PBRM1 (0.46) PBRM1NPC1MITFLMNAPOLB
SCHEMBL10819621 0.79 KDM4E (0.47) PBRM1NPC1MITFLMNAPOLB
SCHEMBL12099224 0.78 PBRM1 (0.45) PBRM1NPC1MITFLMNAPOLB
SCHEMBL12099223 0.78 PBRM1 (0.45) PBRM1NPC1MITFLMNAPOLB
SCHEMBL12163002 0.78 PBRM1 (0.45) PBRM1NPC1MITFLMNAPOLB
Hydrochloric Acid SCHEMBL11264396 0.78 F2 (0.46) PBRM1NPC1MITFLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729114-B2 Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-20 US disclosed
US-20130158018-A1 Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-8222381-B2 Derivatives of monosaccharides for drug discovery ALCHEMIA LIMITED (AU) 2012-07-17 US disclosed
EP-2308854-A1 2,3,6-trisubstituted-4-pyrimidone derivatives Sanofi-Aventis (FR) 2011-04-13 EP disclosed
US-7737287-B2 Anomeric derivatives of monosaccharides ALCHEMIA LIMITED (AU) 2010-06-15 US disclosed
US-7504411-B2 2,3,6-Trisubstituted-4-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-17 US disclosed
US-5451582-A Cholecystokinins and gastrin receptor antagonists MERCK SHARP & DOHME LTD. (GB) 1995-09-19 US disclosed
US-5376685-A Arylhydrazones using as SAMDC inhibitors CIBA-GEIGY CORPORATION (US) 1994-12-27 US disclosed
WO-1993017011-A1 BENZODIAZEPINE DERIVATIVES, AS CCK AND GASTRIN ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 1993-09-02 WO disclosed
US-5238941-A S-adenosylmethionine decarboxylase inhibitors CIBA-GEIGY CORPORATION (US) 1993-08-24 US disclosed
EP-0335832-B1 ARYL HYDRAZONES CIBA-GEIGY AG (CH) 1993-02-10 EP disclosed
US-5118709-A Decarboxylase enzyme inhibitors; antitumor agents CIBA-GEIGY CORPORATION (US) 1992-06-02 US disclosed
US-4971986-A ANTITUMOR AGENTS CIBA-GEIGY CORPORATION (US) 1990-11-20 US disclosed
EP-0335832-A2 Aryl hydrazones CIBA-GEIGY AG (CH) 1989-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158018-A1 Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S CTSS, CTSV, CTSF PBRM1 4438/4885NPC1 74/4885MITF 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.